https://www.marketscreener.com/quote/stock/TAKEDA-PHARMACEUTICAL-COM-6491073/news/Takeda-Receives-Positive-CHMP-Opinion-for-Vedolizumab-IV-for-the-Treatment-of-Active-Chronic-Pouchit-37362488/?utm_source=telegram&utm_medium=social&utm_campaign=share